share_log

bluebird bio | PRE 14A: Preliminary proxy statements relating to merger or acquisition

bluebird bio | PRE 14A: Preliminary proxy statements relating to merger or acquisition

bluebird bio | PRE 14A:並購重組委托聲明
美股SEC公告 ·  2024/09/17 04:08

牛牛AI助理已提取核心訊息

bluebird bio, Inc. (bluebird) has announced the filing of a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The proxy statement includes proposals for stockholder consideration, such as the election of three Class II directors, advisory votes on executive compensation, and amendments to the company's Certificate of Incorporation for a reverse stock split and officer exculpation provisions. The meeting is scheduled for November 6, 2024, at the company's offices in Somerville, Massachusetts. Stockholders are encouraged to vote their shares prior to the meeting. The proxy materials will be available to stockholders via the Internet at www.proxyvote.com, with instructions for accessing the materials and voting described in the Notice of Internet Availability of Proxy Materials mailed to stockholders. The board has recommended voting in favor of all proposals, including the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
bluebird bio, Inc. (bluebird) has announced the filing of a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The proxy statement includes proposals for stockholder consideration, such as the election of three Class II directors, advisory votes on executive compensation, and amendments to the company's Certificate of Incorporation for a reverse stock split and officer exculpation provisions. The meeting is scheduled for November 6, 2024, at the company's offices in Somerville, Massachusetts. Stockholders are encouraged to vote their shares prior to the meeting. The proxy materials will be available to stockholders via the Internet at www.proxyvote.com, with instructions for accessing the materials and voting described in the Notice of Internet Availability of Proxy Materials mailed to stockholders. The board has recommended voting in favor of all proposals, including the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
bluebird bio,Inc.(藍鳥生物)已經向美國證券交易委員會(SEC)提交了2024年股東年會的初步代理文件。該代理文件包括股東考慮的提案,如選舉三名二類董事、對執行薪酬進行諮詢投票,以及修訂公司的公司章程,包括股權合併和高級幹部免責條款。會議定於2024年11月6日在馬薩諸塞州薩默維爾的公司辦公室舉行。鼓勵股東在會議前投票。代理材料將通過互聯網提供給股東,在寄給股東的代理材料互聯網可用通知中描述了訪問材料和投票的說明。董事會建議投票支持所有提案,包括批准安永會計師事務所(Ernst & Young LLP)爲截至2024年12月31日結束的財務年度的獨立註冊公共會計師事務所。
bluebird bio,Inc.(藍鳥生物)已經向美國證券交易委員會(SEC)提交了2024年股東年會的初步代理文件。該代理文件包括股東考慮的提案,如選舉三名二類董事、對執行薪酬進行諮詢投票,以及修訂公司的公司章程,包括股權合併和高級幹部免責條款。會議定於2024年11月6日在馬薩諸塞州薩默維爾的公司辦公室舉行。鼓勵股東在會議前投票。代理材料將通過互聯網提供給股東,在寄給股東的代理材料互聯網可用通知中描述了訪問材料和投票的說明。董事會建議投票支持所有提案,包括批准安永會計師事務所(Ernst & Young LLP)爲截至2024年12月31日結束的財務年度的獨立註冊公共會計師事務所。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。